# US 2023/0144095 A1 · Pyridine derivatives and their use as sodium channel activators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0144095 A1
- Document ID: US20230144095A1
- Status: Published application
- Kind: A1
- Application number: 17/951,640
- Filed: 2022-09-23
- Published: 2023-05-11
- Earliest claimed: 2021-09-24
- Assignees: Xenon Pharmaceuticals Inc.
- Applicants: Xenon Pharmaceuticals Inc.
- Inventors: Verner Alexander Lofstrand; Jung Yun Kim; Helen Clement; Kristen Nicole Burford; Paul Charifson; Shawn Johnstone; Juliette Sabbatani; Jan Felix Scholtes; Wei Zhang; Shaoyi Sun
- Web page: https://patentgrep.com/patent/US20230144095A1

## CPC

- C07D 471/04: Ortho-condensed systems
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure is directed to compounds of formula (1): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

## Claims

### Claim 1

A compound of formula (I):
wherein:
X is ═C(R9)— or ═N—;
Y is ═C(R9)— or —N═; provided that X is not ═N— when Y is —N═ and Y is not —N═ when X is =N—;
R1 is selected from:
wherein:
each n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl; and
R4a is hydrogen;
R2 is —R10—OR11 or —R10—N(R11)2;
or R2 is selected:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
is a double or single bond;
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
or R7 together with R4a form a bond; and
each Ra is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is selected from:
wherein:
each n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl; and
R4a is hydrogen;
R2 is —R10—OR11 or —R10—N(R11)2;
or R2 is selected from:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
is a double or single bond;
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
or R7 together with R4a form a bond; and
each R8 is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 3 (depends on 2)

The compound of claim 2 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl;
R2 is —R10—OR11 or —R10—N(R11)2;
or R2 is selected from:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
is a double or single bond;
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
and
each R8 is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 4 (depends on 3)

The compound of claim 3 wherein:
X is ═C(R9)—;
Y is ═C R9—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl;
R2 is
wherein:
m is 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
is a double or single bond;
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
and
each R8 is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 5 (depends on 4)

The compound of claim 4 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is
wherein:
m is 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, or an optionally substituted O-heterocyclyl;
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl; and
each R7 is independently hydrogen, alkyl, or —R10—C(O)OR12;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 6 (depends on 5)

The compound of claim 5 selected from:
(S)-6-chloro-2-(4-(2,5-difluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-3H-imidazo[4,5-c]pyridine;
2-(4-(2-fluorophenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-3H-imidazo[4,5-b]pyridine;
2-(4-(2-fluorophenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-3H-imidazo[4,5-c]pyridine formic acid salt;
tert-butyl (S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-5-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine;
(S)-1-(2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethan-1-one;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-5-(oxetan-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine;
diethyl (S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-6,7-dihydro-3H-imidazo[4,5-c]pyridine-3,5(4H)-dicarboxylate;
(S)-1-(2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-methylpropan-1-one;
(S)-5-benzyl-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine;
tert-butyl 2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-(2-fluorophenyl)pyridin-3-yl)-3H-imidazo[4,5-c]pyridine;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-(2-fluorophenyl)pyridin-3-yl)-6-methyl-3H-imidazo[4,5-c]pyridine; and
5-(2-(3,3-difluoropyrrolidin-1-yl)-4-(2-fluorophenyl)pyridin-3-yl)-2-methyl-2,4-dihydroimidazo[4,5-c]pyrazole;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 7 (depends on 4)

The compound of claim 4 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is
wherein:
m is 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, or an optionally substituted O-heterocyclyl; and
each R7 is independently hydrogen, alkyl or —R10—C(O)OR12;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 8 (depends on 7)

The compound of claim 7 selected from:
2-(4-(2-fluorophenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(4-(2-chlorophenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(2-(pyrrolidin-1-yl)-4-(o-tolyl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(2-(pyrrolidin-1-yl)-4-(4-(trifluoromethyl)phenyl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(4-phenyl-2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-1H-benzo[d]imidazole;
(S)-2-(4-(2-fluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(4-(3,5-difluorophenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
(3aR,7aR)-2-(2-((S)-3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazole;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazole;
6-(tert-butyl)-2-(4-phenyl-6-(pyrrolidin-1-yl)pyrimidin-5-yl)-1H-benzo[d]imidazole;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-1,4,5,6-tetrahydrocyclopenta[d]imidazol-5-ol;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-6-methoxy-4,5,6,7-tetrahydro-1H-benzo[d]imidazole;
(S)-2-(2-((S)-3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-6-methoxy-4,5,6,7-tetrahydro-1H-benzo[d]imidazole; and
(R)-2-(2-((S)-3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-6-methoxy-4,5,6,7-tetrahydro-1H-benzo[d]imidazole;
2-(2-((S)-3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-6-methoxy-4,5,6,7-tetrahydro-1H-benzo[d]imidazole;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)benzo[d]oxazole;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazole;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 9 (depends on 4)

The compound of claim 4 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl;
R2 is
wherein:
m is 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, or an optionally substituted O-heterocyclyl;
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl; and
each R7 is independently hydrogen, alkyl or —R10—C(O)OR12;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 10 (depends on 9)

The compound of claim 9 selected from:
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-6,6-dimethyl-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
(S)-2-(4-(2,5-difluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-(2-fluorophenyl)pyridin-3-yl)-1,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(4-(2,5-difluorophenyl)-2-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl)-1,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-(1H-indazol-5-yl)pyridin-3-yl)-1,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-(3-fluorophenyl)pyridin-3-yl)-1,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(4-phenyl-2-(pyrrolidin-1-yl)pyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(4-(2,5-difluorophenyl)-2-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl)-6,6-dimethyl-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-((3S,4R)-3,4-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(4-(2,3-difluorophenyl)-2-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
1-(4-phenyl-3-(3,4,6,7-tetrahydropyrano[3,4-d]imidazol-2-yl)pyridin-2-yl)pyrrolidine-3-carbonitrile;
2′-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-4′,7′-dihydro-3′H-spiro[cyclobutane-1,6′-pyrano[3,4-d]imidazole];
2-(4-phenyl-2-(3-(trifluoromethyl)pyrrolidin-1-yl)pyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole; and
2-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-4,4-dimethyl-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 11 (depends on 4)

The compound of claim 4 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is
wherein;
m is 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
and
each R8 is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 12 (depends on 11)

The compound of claim 11 selected from:
5-(4-(2-fluorophenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine;
4-(2-fluorophenyl)-3-(5-isobutyl-4,5-dihydro-1H-imidazol-2-yl)-2-(pyrrolidin-1-yl)pyridine;
(S)-2-(4-(2-fluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole;
(S)—N-butyl-5-(4-(2-fluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-3-(5-isopentyl-1,3,4-oxadiazol-2-yl)pyridin-4-yl)phenol;
(S)-2-(4-(2-fluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-5-isopentyl-1,3,4-oxadiazole;
(S)-2-(3-fluoropyrrolidin-1-yl)-4-phenyl-3-(3-(pyridin-3-yl)-1H-pyrazol-5-yl)pyridine;
(S)-2-(3-fluoropyrrolidin-1-yl)-3-(3-(4-isopropylphenyl)-1H-pyrazol-5-yl)-4-phenylpyridine;
(S)-1-(6-chloropyridin-3-yl)-3-(4-(2-fluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)imidazolidin-2-one;
(S)-1-(6-chloropyridin-3-yl)-3-(4-(2-fluorophenyl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one;
2-((S)-3-fluoropyrrolidin-1-yl)-3-(5-methyl-4,5-dihydro-1H-imidazol-2-yl)-4-phenylpyridine;
(S)-3-(4-bromo-5-methyl-1H-imidazol-2-yl)-2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridine;
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-5-(4-isopropylphenyl)-1,3,4-oxadiazole;
tert-butyl (S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate;
(S)-2-(3-fluoropyrrolidin-1-yl)-3-(4-methyl-5-(trifluoromethyl)-1H-imidazol-2-yl)-4-phenylpyridine;
2-(3,3-difluoropyrrolidin-1-yl)-3-(5-methyl-4-phenyl-1H-imidazol-2-yl)-4-phenylpyridine;
5-(tert-butyl)-3-(2-(3,3-difluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-1,2,4-oxadiazole; and
(S)-2-(3-fluoropyrrolidin-1-yl)-4-phenyl-3-(3-phenyl-1H-1,2,4-triazol-5-yl)pyridine;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 13 (depends on 3)

The compound of claim 3 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
n is 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is —R10—OR11 or —R10—N(R11)2;
or R2 is selected from:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, o-R10—C(O)R12, —R10—N(R11)2, or an optionally substituted O-heterocyclyl;
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl; and
each R7 is independently hydrogen, alkyl, or —R10—C(O)OR12;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 14 (depends on 13)

The compound of claim 13 selected from:
4-(3-(1H-benzo[d]imidazol-2-yl)-4-(o-tolyl)pyridin-2-yl)morpholine;
2-(2-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)-1H-benzo[d]imidazole;
4-(3-(3-(4-isopropylphenyl)-1H-pyrazol-5-yl)-4-phenylpyridin-2-yl)morpholine;
4-(3-((3aR,7aR)-3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazol-2-yl)-4-phenylpyridin-2-yl)morpholine;
4-(4-phenyl-3-(4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)morpholine;
2-(2-morpholino-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(3,3-difluoroazetidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(4-phenyl-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-cyclobutoxy-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(3,3-difluoropiperidin-1-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
2-(2-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
4-phenyl-3-(3,4,6,7-tetrahydropyrano[3,4-d]imidazol-2-yl)-N-((1-(trifluoromethyl)cyclobutyl)methyl)pyridin-2-amine;
2-(4-phenyl-2-(tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole; and
2-(2-(3,6-dihydro-2H-pyran-4-yl)-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 15 (depends on 2)

The compound of claim 2 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is
wherein:
each n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11; and
R4a is hydrogen;
R2 is selected from:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
R3 is
wherein:
p is 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12 or —R10—N(R11)2; and
R7 together with R4a form a bond;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 16 (depends on 15)

The compound of claim 15 selected from:
4-(benzo[c]benzo[4,5]imidazo[2,1-a][2,7]naphthyridin-1-yl)morpholine;
1-(4-methylpiperazin-1-yl)benzo[c]benzo[4,5]imidazo[2,1-a][2,7]naphthyridine; and
1-(pyrrolidin-1-yl)benzo[c]benzo[4,5]imidazo[2,1-a][2,7]naphthyridine;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 17 (depends on 2)

The compound of claim 2 wherein:
X is ═C(R9)—;
Y is ═C(R9)—;
R1 is selected from:
wherein:
each n is independently 1, 2 or 3; and
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is selected from:
wherein:
each m is independently 1 or 2; and
each R5 is independently hydrogen, halo, alkyl or haloalkyl;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, or —R10—C(O)R12, —R10—N(R11)2; and
each R7 is independently hydrogen, alkyl or —R10—C(O)OR12;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 18 (depends on 17)

The compound of claim 17 selected from:
2-(2,4-di(1H-pyrazol-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(2′-(pyrrolidin-1-yl)-[2,4′-bipyridin]-3′-yl)-1H-benzo[d]imidazole;
2-(4-(1H-pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
(S)-2-(4-(cyclopent-1-en-1-yl)-2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)-1H-benzo[d]imidazole;
2-(2′-(pyrrolidin-1-yl)-[2,4′-bipyridin]-3′-yl)-1H-benzo[d]imidazole; and
2-(2′-(3,3-difluoropyrrolidin-1-yl)-[2,4′-bipyridin]-3′-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 19 (depends on 1)

The compound of claim 1 wherein:
X is ═N— and Y is ═C(R9) or X is ═C(R9) and Y is ═N—;
R1 is
wherein:
n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is selected from:
wherein:
m is 1 or 2;
R5 is hydrogen, halo, alkyl, haloalkyl or —R10—CN;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, or an optionally substituted O-heterocyclyl; and
each R7 is independently hydrogen, alkyl or —R10—C(O)OR12;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 20 (depends on 19)

The compound of claim 19 selected from:
2-(5-phenyl-3-(pyrrolidin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole; and
4-(5-phenyl-4-(4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)morpholine;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 21 (depends on 1)

The compound of claim 1 wherein:
X is ═C(R9) and Y is ═C(R9);
R1 is
wherein:
n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
R2 is
wherein:
m is 1 or 2;
R5 is hydrogen, halo, alkyl, haloalkyl or —R10—CN;
R3 is selected from:
wherein:
each p is independently 1, 2, 3, or 4; and
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, or an optionally substituted O-heterocyclyl;
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 22 (depends on 21)

The compound of claim 21 selected from:
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)imidazo[1,2-a]pyridine; and
(S)-2-(2-(3-fluoropyrrolidin-1-yl)-4-phenylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 23

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I):
wherein:
X is ═C(R9)— or ═N—;
Y is ═C(R9)— or —N═; provided that X is not ═N— when Y is —N═ and Y is not —N═ when X is =N—;
R1 is selected from:
wherein:
each n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl; and
R4a is hydrogen;
R2 is —R10—OR11 or —R10—N(R11)2;
or R2 is selected:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
is a double or single bond;
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR11, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
or R7 together with R4a form a bond; and
each Ra is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 24

A method of treating a disease or condition in a mammal modulated by a voltage-gated sodium channel, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I):
wherein:
X is ═C(R9)— or ═N—;
Y is ═C(R9)— or —N═; provided that X is not ═N— when Y is —N═ and Y is not —N═ when X is =N—;
R1 is selected from:
wherein:
each n is independently 1, 2 or 3;
each R4 is independently hydrogen, halo, alkyl, haloalkyl, or —R10—OR11;
or two adjacent R4's, together with the carbons to which they are attached, form an optionally substituted N-heteroaryl; and
R4a is hydrogen;
R2 is —R10—OR11 or —R10—N(R11)2;
or R2 is selected:
wherein:
each m is independently 1 or 2;
each R5 is independently hydrogen, halo, alkyl, haloalkyl or —R10—CN;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted O-heterocyclyl;
or two R5's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
or two adjacent R5's, together with the carbons to which they are attached, form an optionally substituted cycloalkyl;
R3 is selected from:
wherein:
is a double or single bond;
each p is independently 1, 2, 3, or 4;
each R6 is independently hydrogen, halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, —R10—OR1, —R10—C(O)OR12, —R10—C(O)R12, —R10—N(R11)2, an optionally substituted O-heterocyclyl or
or two R6's, together with the carbon to which they are both attached, form an optionally substituted cycloalkyl;
each R7 is independently hydrogen, alkyl, —R10—C(O)OR12 or
or R7 together with R4a form a bond; and
each R8 is independently hydrogen, alkyl or halo,
each R9 is independently hydrogen or alkyl;
each R10 is independently a direct bond or an optionally substituted alkylene chain;
each R11 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloakyl or optionally substituted cycloalkylalkyl; and
each R12 is hydrogen, alkyl or optionally substituted aralkyl;
as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
